（编辑 丛可心） 证券日报网1月8日讯 ，联化科技在接受调研者提问时表示，公司部分植保客户的产品确实面临专利到 期的情况，但预计其对公司的整体影响较为有限。公司依据过往的生产经验，可以持续进行产品和技术 的迭代升级。在产品技术迭代升级过程中，对现有生产装置的改造投入相对有限，远低于新建产能的资 本开支。若投入较大，客户亦愿意共同承担。公司预计，通过迭代升级产品和技术所带来的业务增量能 够有效覆盖因专利到期导致的存量业务的自然萎缩，从而保持该业务板块收入的整体稳定。 ...

12月19日，联化科技（002250）披露投资者关系活动记录，公司于当日以特定对象调研形式接待了国海 证券、野村资管、易方达、湘财基金、国诚投资等5家机构的调研。公司高级副总裁、董秘陈飞彪及证 券事务代表戴依依参与接待，就公司植保业务布局、医药CDMO发展、研发创新方向及资本运作计划等 核心问题与机构进行了深入交流。 投资者关系活动基本信息投资者关系活动类别：特定对象调研时间：2025年12月19日地点：上海办会议 室参与单位名称：国海证券、野村资管、易方达、湘财基金、国诚投资上市公司接待人员：高级副总 裁、董秘 陈飞彪；证券事务代表 戴依依 调研核心内容解读植保业务：加码海外基地布局 构建差异化供应链 针对机构关注的植保业务规划，公司表示，植保行业集中度较高，公司已与多家国际农化/植保企业建 立长期战略合作伙伴关系，业务覆盖产品生命周期全阶段。为满足客户供应链布局需求，公司正将马来 西亚打造为"差异化的供应链布局"第二海外基地，协同中国、英国及马来西亚三地生产基地，利用中国 完善的化工供应链配套、英国及马来西亚灵活的生产及登记政策，为客户提供全产业链一站式服务。未 来，植保业务CDMO领域有望持续稳步发展。 ...

证券日报网12月16日讯联化科技（002250）在回答调研者提问时表示，部分植保产品专利到期整体上对 公司冲击有限，这主要得益于公司"大客户战略"和CDMO模式的支撑。即使特定产品专利到期，根据公 司与核心客户签订的长期框架协议，相关产品仍将仅向协议客户供应，这种深度绑定保障了业务的稳定 性。同时，公司在长期为客户提供CDMO服务时，不断进行生产优化，降本增效，提升产品的市场竞争 力。另一方面，公司亦正通过建设马来西亚基地等举措，将产能重点投向新的专利期内产品，以持续驱 动增长。 ...

Core Insights - The article highlights the recent significant developments in Jinshan, including the inauguration of major projects such as the Syngenta plant protection products technology and engineering laboratory and the Lexus office building, marking a turning point for the region [1][2]. Group 1: Major Projects and Developments - Jinshan has seen a series of major projects over the past five years, including the opening of the Shanghai Lego Resort in November 2021, the commencement of the Ruijin Hospital Jinshan District in June 2023, and the announcement of the Syngenta Global Plant Protection Innovation Center in February 2025 [2]. - The Lexus electric vehicle project is expected to be completed by August 2026 and commence production in 2027, with an initial workforce of approximately 80 employees [1][2]. Group 2: Economic Impact and Community Response - The influx of projects has generated mixed reactions, with some skepticism regarding the economic impact of the Lexus project compared to larger investments in other sectors [2]. - Experts emphasize that while the investment in vehicle manufacturing may not be as substantial as in semiconductor industries, it can significantly boost GDP through local supply chain development [2]. Group 3: Transformation and Strategic Initiatives - Jinshan's transformation from a pollution-heavy industrial base to a greener, high-end chemical materials hub has involved significant investment, totaling around 36 billion yuan over ten years, with 810 environmental projects completed [3][4]. - The region's high-end chemical new materials industry has reached a production value of nearly 170 billion yuan, contributing to its recognition as a key industrial cluster in Shanghai [3][4]. Group 4: Future Directions and Governance - Jinshan is focusing on efficient service delivery for project implementation, adopting measures such as "full-service agency" and "chain-style support" to enhance its business environment [5]. - The region aims to integrate industrial, spatial, and governance transformations, emphasizing innovation in technology, digitalization, and cultural tourism to drive future growth [5][6].

Core Insights - Dabeinong's stock increased by 1.67% on November 11, with a trading volume of 575 million yuan [1] - The company reported a net profit growth of 92.56% year-on-year for the first nine months of 2025 [2] Financing and Trading Activity - On November 11, Dabeinong had a financing buy-in of 82.04 million yuan and a net financing buy of 3.39 million yuan, with a total financing balance of 943 million yuan [1] - The financing balance represents 5.07% of the circulating market value and is above the 80th percentile of the past year [1] - Dabeinong's short selling activity included a repayment of 17,200 shares and a sale of 83,900 shares, with a short selling balance of 13.06 million yuan, also above the 90th percentile of the past year [1] Company Overview - Dabeinong was established on October 18, 1994, and listed on April 9, 2010, focusing on feed production, sales, and crop seed cultivation [1] - The company's revenue composition includes 63.42% from feed products, 25.08% from pig farming products, and smaller contributions from other agricultural products [1] Shareholder and Institutional Holdings - As of September 30, 2025, Dabeinong had 227,400 shareholders, a decrease of 5.84% from the previous period [2] - The top institutional shareholder is Guotai CSI Livestock Breeding ETF, holding 76.99 million shares, an increase of 27.76 million shares [2] - Hong Kong Central Clearing Limited is the fifth-largest shareholder, with 51.63 million shares, an increase of 14.93 million shares [2]

Core Insights - Bayer has participated in the China International Import Expo (CIIE) for eight consecutive years, leveraging the event's spillover effects to accelerate innovation and deepen cooperation in the Chinese market [1][4] - The company has witnessed significant achievements, including over 50 product debuts and nearly 40 important contracts signed with various partners, enhancing collaboration in technology and innovation [1][3] Group 1: Investment and Market Environment - Bayer views China as a vital pillar in its global strategy, emphasizing that investing in China equates to investing in the future [4] - The continuous improvement of the business environment and intellectual property protection in China has positively influenced Bayer's strategic layout in the country [1][2] Group 2: Product Development and Innovation - In the prescription drug sector, China is enhancing its patent protection system, encouraging research and development of innovative drugs [3] - Bayer has launched over 10 new consumer health products in recent years, focusing on areas such as digestive health, skin health, and nutritional supplements [3] Group 3: Future Plans and Collaborations - Bayer is set to open the "Bayer Yizhuang Open Innovation Center" and has deepened research collaborations with top Chinese universities, completing over 100 research projects with Tsinghua University and Peking University [4] - The "Bayer Health Consumer Products China Innovation Cooperation Center" will be inaugurated in October 2024 in Shanghai, aiming to foster reliable health solutions through integrated innovation [4] Group 4: CIIE Participation Highlights - At the eighth CIIE, Bayer's exhibition area covered 800 square meters, showcasing 26 highlight products, including 5 global debuts and 8 China debuts [6] - Bayer aims to continue its commitment to open cooperation, focusing on sustainable high-quality development in healthcare and agricultural technology [6]

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected investment return that will outperform the market benchmark by over 15% in the next 6-12 months [6][14]. Core Views - The company reported a revenue of 21.678 billion yuan for the first three quarters of 2025, a year-on-year increase of 0.72%. The net profit attributable to shareholders was a loss of 423 million yuan, narrowing by 77% year-on-year [1]. - The agricultural chemical industry is experiencing a recovery, with the company expected to benefit from this trend due to its leading position in the global crop protection sector [3]. - The report projects a gradual improvement in profitability, with net profits expected to be -512 million yuan in 2025, followed by positive profits in 2026 and 2027 [3]. Summary by Sections Financial Performance - For Q3 2025, the company achieved a revenue of 6.654 billion yuan, a year-on-year increase of 0.62%, but a quarter-on-quarter decrease of 15.25%. The net profit attributable to shareholders was a loss of 342 million yuan, narrowing by 63.69% year-on-year but widening by 47.94% quarter-on-quarter [1]. - The gross margin improved by 4.0 percentage points to 26.2% in the first three quarters of 2025, driven by operational efficiency and reduced inventory costs [2]. Industry Outlook - The agricultural chemical industry is seeing a recovery in demand, with channel inventories returning to pre-2020 levels. The domestic pesticide raw material price index increased by 1.7% in Q3 2025 [3]. - The company is well-positioned to benefit from the recovery in agricultural chemical prices, with certain product prices stabilizing after previous declines [3]. Profitability Forecast - The report revises the profit forecast for 2025-2027, expecting net profits of -512 million yuan, 396 million yuan, and 703 million yuan respectively, reflecting a significant improvement in profitability over the forecast period [3][5].

Core Insights - Syngenta reported a revenue of $20.9 billion for the first three quarters of 2025, a 2% year-on-year decline, while EBITDA reached $3.4 billion, reflecting a 25% increase [1] - In Q3 2025, Syngenta's revenue was $6.4 billion, down 6% year-on-year [1] Business Segment Performance - For the first nine months of 2025, Syngenta's crop protection revenue grew by 3% to $9.8 billion, while seed business revenue was $3.3 billion, up 1% [1] - Syngenta's revenue in China for the first nine months of 2025 was $6.5 billion, a decline of 11% year-on-year, influenced by the orderly contraction of grain trading and market price pressures [1] - During the same period, the revenue of Syngenta's subsidiary, Adama, remained flat at $3 billion compared to the previous year [1] Future Outlook - Despite challenges in the global agricultural market and continued pressure on farmer incomes in many regions, Syngenta expects to maintain stable revenue and further enhance profitability by the end of 2025 [1]

Core Viewpoint - Zhongyin Securities report indicates that Lianhua Technology achieved a net profit attributable to shareholders of 224 million yuan in H1 2025, representing a year-on-year increase of 1,481.94% [1] Financial Performance - In Q2 2025, the company realized a net profit attributable to shareholders of 174 million yuan, showing a year-on-year increase of 1,419.69% and a quarter-on-quarter increase of 250.44% [1] - The company's revenue and net profit attributable to shareholders both experienced year-on-year growth in H1 2025, with a significant increase in net profit mainly due to cost reduction and efficiency enhancement efforts [1] Operational Efficiency - The substantial increase in net profit is attributed to the company's commitment to reducing costs and improving operational efficiency, as well as an increase in the capacity utilization rate of its plant protection business and adjustments in product structure, leading to higher gross margins [1] - The pharmaceutical business also saw significant growth due to concentrated shipments [1] Strategic Direction - The company plans to leverage its existing advantages in phosgene and fluorination synthesis technologies, forming a comprehensive "synthesis + engineering" technology approach [1] - There is an intention to extend into niche markets such as battery chemicals, focusing on market and customer expansion [1] Industry Outlook - The company is optimistic about the recovery in the plant protection industry and the orderly advancement of its product layout across various business segments, maintaining a "buy" rating [1]

Core Viewpoint - The company has established itself as a significant strategic supplier in the agricultural protection industry, ranking among the top five companies [1] Group 1: Strategic Partnerships - The company has successfully become a strategic supplier for several international pharmaceutical giants and has partnered with many of the top 20 pharmaceutical companies [1] - This recognition has provided the company with a competitive product advantage and broad market opportunities [1] Group 2: Business Segments - The company's functional chemicals division primarily focuses on self-produced and self-sold products [1] - Key areas covered by this division include personal care and battery sectors [1]